• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

N-Benzyl 5-borono-2-methoxybenzenesulfonamide: A Key Intermediate in Modern Pharmaceutical Synthesis

N-Benzyl 5-borono-2-methoxybenzenesulfonamide, a compound with the CAS number 874219-51-9, represents a significant advancement in the field of pharmaceutical chemistry. This compound serves as a crucial intermediate in the synthesis of various biologically active molecules, particularly those targeting neurological and inflammatory disorders. Its unique structural features, including the presence of both a boronic acid group and a methoxy-substituted benzene ring, make it an invaluable tool for medicinal chemists.

The utility of N-Benzyl 5-borono-2-methoxybenzenesulfonamide stems from its ability to participate in cross-coupling reactions, which are fundamental to the construction of complex organic molecules. Specifically, the boronic acid moiety allows for Suzuki-Miyaura coupling, a reaction that has become indispensable in drug discovery. This capability has been leveraged in recent years to develop novel therapeutic agents with enhanced efficacy and reduced side effects.

In recent studies, researchers have highlighted the role of this compound in the development of inhibitors for enzymes involved in pain signaling pathways. The methoxy group on the benzene ring contributes to the compound's lipophilicity, which is often critical for achieving optimal pharmacokinetic properties. Furthermore, the sulfonamide functionality enhances binding affinity to target proteins, making it an attractive scaffold for drug design.

One notable application of N-Benzyl 5-borono-2-methoxybenzenesulfonamide is in the synthesis of small molecule inhibitors targeting interleukin-1β (IL-1β), a key cytokine in inflammatory responses. Preclinical studies have demonstrated that compounds derived from this intermediate exhibit potent anti-inflammatory properties without significant immunosuppressive effects. This finding underscores the potential of boronic acid-containing sulfonamides as therapeutic candidates.

The synthesis of N-Benzyl 5-borono-2-methoxybenzenesulfonamide involves multi-step organic transformations that require precise control over reaction conditions. The introduction of the boronic acid group typically employs palladium-catalyzed cross-coupling reactions, while the sulfonamide moiety is incorporated through nucleophilic substitution or condensation reactions. These synthetic strategies highlight the compound's versatility and its suitability for large-scale production.

Advances in computational chemistry have further enhanced the design and optimization of derivatives based on N-Benzyl 5-borono-2-methoxybenzenesulfonamide. Molecular modeling techniques allow researchers to predict binding interactions and optimize pharmacological properties before experimental synthesis. This approach has accelerated the discovery pipeline for new drugs targeting neurological disorders, including Alzheimer's disease and Parkinson's disease.

The growing interest in boronic acid-containing compounds is also driven by their stability and bioavailability. Unlike some traditional heterocyclic scaffolds, boronic acids exhibit greater resistance to metabolic degradation, ensuring prolonged circulation and improved therapeutic outcomes. This characteristic has made derivatives of N-Benzyl 5-borono-2-methoxybenzenesulfonamide particularly valuable in treating chronic conditions where sustained drug delivery is essential.

In conclusion, N-Benzyl 5-borono-2-methoxybenzenesulfonamide (CAS no. 874219-51-9) represents a cornerstone in modern pharmaceutical synthesis. Its unique structural features enable participation in diverse chemical transformations, making it an indispensable intermediate for drug development. As research continues to uncover new therapeutic applications, this compound is poised to play an increasingly pivotal role in addressing some of today's most pressing medical challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)